The University of Southampton
University of Southampton Institutional Repository

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow card scheme': Literature review, descriptive and qualitative analyses, and questionnaire surveys

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow card scheme': Literature review, descriptive and qualitative analyses, and questionnaire surveys
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow card scheme': Literature review, descriptive and qualitative analyses, and questionnaire surveys

Background: The monitoring of adverse drug reactions (ADRs) through pharmacovigilance is vital to patient safety. Spontaneous reporting of ADRs is one method of pharmacovigilance, and in the UK this is undertaken through the Yellow Card Scheme (YCS). Yellow Card reports are submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) by post, telephone or via the internet. The MHRA electronically records and reviews information submitted so that important safety issues can be detected. While previous studies have shown differences between patient and healthcare professional (HCP) reports for the types of drugs and reactions reported, relatively little is known about the pharmacovigilance impact of patient reports. There have also been few studies on the views and experiences of patients/consumers on the reporting of suspected ADRs. Objectives: To evaluate the pharmacovigilance impact of patient reporting of ADRs by analysing reports of suspected ADRs from the UK YCS and comparing reports from patients and HCPs. To elicit the views and experiences of patients and the public about patient reporting of ADRs. Design: (1) Literature review and survey of international experiences of consumer reporting of ADRs; (2) descriptive analysis of Yellow Card reports; (3) signal generation analysis of Yellow Card reports; (4) qualitative analysis of Yellow Card reports; (5) questionnaire survey of patients reporting on Yellow Cards; (6) qualitative analysis of telephone interviews with patient reporters to the scheme; (7) qualitative analysis of focus groups and usability testing of the patient YCS; and (8) national omnibus telephone survey of public awareness of the YCS. Participants: Patients (n = 5180) and HCPs (n = 20,949) submitting Yellow Card reports from October 2005 to September 2007. Respondents to questionnaire survey (n = 1362). Participants at focus groups and usability testing sessions (n = 40). National omnibus telephone survey (n = 2028). Setting: The literature review included studies in English from across the world. All other components included populations from the UK; the omnibus survey was restricted to Great Britain. Interventions: None. Main outcome measures: Characteristics of patient reports: types of drug and suspected ADR reported; seriousness of reports; and content of reports. The relative contributions of patient reports and of HCP reports to signal generation. Views and experiences of patient reporters. Views of members of the public about the YCS, including user-friendliness and usability of different ways of patient reporting. Public awareness of the YCS. Suggestions for improving patient reporting to the YCS. Results: Compared with HCPs, patient reports to the YCS contained a higher median number of suspected ADRs per report, and described reactions in more detail. The proportions of reports categorised as 'serious' were similar; the patterns of drugs and reactions reported differed. Patient reports were richer in their descriptions of reactions than those from HCPs, and more often noted the effects of ADRs on patients' lives. Combining patient and HCP reports generated more potential signals than HCP reports alone; some potential signals in the 'HCP-only' data set were lost when combined with patient reports, but fewer than those gained; the addition of patient reports to HCP reports identified 47 new 'serious' reactions not previously included in 'Summaries of Product Characteristics'. Most patient reporters found it fairly easy to make reports, although improvements to the scheme were suggested, including greater publicity and the redesign of web- and paper-based reporting systems. Among members of the public, 8.5% were aware of the YCS in 2009. Conclusions: Patient reporting of suspected ADRs has the potential to add value to pharmacovigilance by reporting types of drugs and reactions different from those reported by HCPs; generating new potential signals; and describing suspected ADRs in enough detail to provide useful information on likely causality and impact on patients' lives. These findings suggest that further promotion of patient reporting to the YCS is justified, along with improvements to existing reporting systems. In order of priority, future work should include further investigation of (1) the pharmacovigilance impact of patient reporting in a longer-term study; (2) the optimum approach to signal generation analysis of patient and HCP reports; (3) the burden of ADRs in terms of impact on patients' lives; (4) the knowledge and attitudes of HCPs towards patient reporting of ADRs; (5) the value of using patient reports of ADRs to help other patients and HCPs who are seeking information on patient experiences of ADRs; and (6) the impact of increasing publicity and/or enhancements to reporting systems on the numbers and types of Yellow Card reports from patients. Funding: The National Institute for Health Research Health Technology Assessment programme.

1366-5278
1-234
Avery, A. J.
ba667df1-c7e8-4812-855c-8f5d8c37ed86
Anderson, C.
3dc8da93-a2c9-4c0e-80f4-5179fc083411
Bond, C. M.
bc06f62c-0c08-47da-a117-412a2fe62fa3
Fortnum, H.
c6d26f3d-0d40-483b-ac08-40eaa6e76840
Gifford, A.
e6353471-1147-48c7-9ae3-40a27696e6e8
Hannaford, P. C.
b3b54676-6dd4-4367-bc2d-684ab6ac9709
Hazell, L.
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Krska, J.
e2251c17-f925-4c68-94f9-8e9ac18263a8
Lee, A. J.
8ed5b48b-a47b-474d-bc20-d2e01996c6cc
McLernon, D. J.
efe3567f-dea6-47ba-9d20-4cdd1739c8df
Murphy, E.
3a9806e6-f61d-4469-a81b-28603729ff19
Shakir, S.
fd9b34d3-e365-4a60-bc28-b477a1f98026
Watson, M. C.
cb784a24-f867-4840-9719-a0ece3cd40f7
Avery, A. J.
ba667df1-c7e8-4812-855c-8f5d8c37ed86
Anderson, C.
3dc8da93-a2c9-4c0e-80f4-5179fc083411
Bond, C. M.
bc06f62c-0c08-47da-a117-412a2fe62fa3
Fortnum, H.
c6d26f3d-0d40-483b-ac08-40eaa6e76840
Gifford, A.
e6353471-1147-48c7-9ae3-40a27696e6e8
Hannaford, P. C.
b3b54676-6dd4-4367-bc2d-684ab6ac9709
Hazell, L.
1c9036d8-13c0-4fe1-88be-9a926dc003b5
Krska, J.
e2251c17-f925-4c68-94f9-8e9ac18263a8
Lee, A. J.
8ed5b48b-a47b-474d-bc20-d2e01996c6cc
McLernon, D. J.
efe3567f-dea6-47ba-9d20-4cdd1739c8df
Murphy, E.
3a9806e6-f61d-4469-a81b-28603729ff19
Shakir, S.
fd9b34d3-e365-4a60-bc28-b477a1f98026
Watson, M. C.
cb784a24-f867-4840-9719-a0ece3cd40f7

Avery, A. J., Anderson, C., Bond, C. M., Fortnum, H., Gifford, A., Hannaford, P. C., Hazell, L., Krska, J., Lee, A. J., McLernon, D. J., Murphy, E., Shakir, S. and Watson, M. C. (2011) Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow card scheme': Literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technology Assessment, 15 (20), 1-234. (doi:10.3310/hta15200).

Record type: Review

Abstract

Background: The monitoring of adverse drug reactions (ADRs) through pharmacovigilance is vital to patient safety. Spontaneous reporting of ADRs is one method of pharmacovigilance, and in the UK this is undertaken through the Yellow Card Scheme (YCS). Yellow Card reports are submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) by post, telephone or via the internet. The MHRA electronically records and reviews information submitted so that important safety issues can be detected. While previous studies have shown differences between patient and healthcare professional (HCP) reports for the types of drugs and reactions reported, relatively little is known about the pharmacovigilance impact of patient reports. There have also been few studies on the views and experiences of patients/consumers on the reporting of suspected ADRs. Objectives: To evaluate the pharmacovigilance impact of patient reporting of ADRs by analysing reports of suspected ADRs from the UK YCS and comparing reports from patients and HCPs. To elicit the views and experiences of patients and the public about patient reporting of ADRs. Design: (1) Literature review and survey of international experiences of consumer reporting of ADRs; (2) descriptive analysis of Yellow Card reports; (3) signal generation analysis of Yellow Card reports; (4) qualitative analysis of Yellow Card reports; (5) questionnaire survey of patients reporting on Yellow Cards; (6) qualitative analysis of telephone interviews with patient reporters to the scheme; (7) qualitative analysis of focus groups and usability testing of the patient YCS; and (8) national omnibus telephone survey of public awareness of the YCS. Participants: Patients (n = 5180) and HCPs (n = 20,949) submitting Yellow Card reports from October 2005 to September 2007. Respondents to questionnaire survey (n = 1362). Participants at focus groups and usability testing sessions (n = 40). National omnibus telephone survey (n = 2028). Setting: The literature review included studies in English from across the world. All other components included populations from the UK; the omnibus survey was restricted to Great Britain. Interventions: None. Main outcome measures: Characteristics of patient reports: types of drug and suspected ADR reported; seriousness of reports; and content of reports. The relative contributions of patient reports and of HCP reports to signal generation. Views and experiences of patient reporters. Views of members of the public about the YCS, including user-friendliness and usability of different ways of patient reporting. Public awareness of the YCS. Suggestions for improving patient reporting to the YCS. Results: Compared with HCPs, patient reports to the YCS contained a higher median number of suspected ADRs per report, and described reactions in more detail. The proportions of reports categorised as 'serious' were similar; the patterns of drugs and reactions reported differed. Patient reports were richer in their descriptions of reactions than those from HCPs, and more often noted the effects of ADRs on patients' lives. Combining patient and HCP reports generated more potential signals than HCP reports alone; some potential signals in the 'HCP-only' data set were lost when combined with patient reports, but fewer than those gained; the addition of patient reports to HCP reports identified 47 new 'serious' reactions not previously included in 'Summaries of Product Characteristics'. Most patient reporters found it fairly easy to make reports, although improvements to the scheme were suggested, including greater publicity and the redesign of web- and paper-based reporting systems. Among members of the public, 8.5% were aware of the YCS in 2009. Conclusions: Patient reporting of suspected ADRs has the potential to add value to pharmacovigilance by reporting types of drugs and reactions different from those reported by HCPs; generating new potential signals; and describing suspected ADRs in enough detail to provide useful information on likely causality and impact on patients' lives. These findings suggest that further promotion of patient reporting to the YCS is justified, along with improvements to existing reporting systems. In order of priority, future work should include further investigation of (1) the pharmacovigilance impact of patient reporting in a longer-term study; (2) the optimum approach to signal generation analysis of patient and HCP reports; (3) the burden of ADRs in terms of impact on patients' lives; (4) the knowledge and attitudes of HCPs towards patient reporting of ADRs; (5) the value of using patient reports of ADRs to help other patients and HCPs who are seeking information on patient experiences of ADRs; and (6) the impact of increasing publicity and/or enhancements to reporting systems on the numbers and types of Yellow Card reports from patients. Funding: The National Institute for Health Research Health Technology Assessment programme.

This record has no associated files available for download.

More information

Published date: 1 May 2011

Identifiers

Local EPrints ID: 439085
URI: http://eprints.soton.ac.uk/id/eprint/439085
ISSN: 1366-5278
PURE UUID: 38cca760-39bf-4b53-9319-2b6ade20df48
ORCID for L. Hazell: ORCID iD orcid.org/0000-0002-5962-0648

Catalogue record

Date deposited: 02 Apr 2020 16:35
Last modified: 16 Mar 2024 06:54

Export record

Altmetrics

Contributors

Author: A. J. Avery
Author: C. Anderson
Author: C. M. Bond
Author: H. Fortnum
Author: A. Gifford
Author: P. C. Hannaford
Author: L. Hazell ORCID iD
Author: J. Krska
Author: A. J. Lee
Author: D. J. McLernon
Author: E. Murphy
Author: S. Shakir
Author: M. C. Watson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×